HL192 well tolerated in volunteers in Parkinson’s clinical trial
HL192, an experimental oral therapy being developed to treat Parkinson’s disease, was tolerated well by healthy volunteers in a first-in-human clinical trial. The therapy’s developers — Nurron Pharmaceuticals, working in partnership with Hanall Biopharma and Daewoong Pharmaceutical — said they are planning a trial to…